At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HIMZ DEFIANCE DAILY TARGET 2X LONG HIMS ETF
Pre-Mkt 07-21 05:39:20 EDT
41.89
-0.42
-0.99%
盘前43.21
+1.32+3.16%
04:54 EDT
High44.22Low41.01Vol154.90K
Open41.69D1 Closing42.31Amplitude7.58%
Mkt Cap91.30MTradable Cap91.30MTotal Shares2.18M
T/O6.61MT/O Rate7.11%Tradable Shares2.18M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares Valued at $229,075.99
Reuters  ·  04:31
Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares Valued at $229,075.99
Trump's FDA May Soon Back Peptides. Should You Buy In?
Dow Jones  ·  07-18
Trump's FDA May Soon Back Peptides. Should You Buy In?
Hims & Hers Accounting Chief Exits
Dow Jones  ·  07-18
Hims & Hers Accounting Chief Exits
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
THOMSON REUTERS  ·  07-18
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
Cboe data shows mixed options sentiment in Hims and Hers Health with shares down 9.35%
TIPRANKS  ·  07-17
Cboe data shows mixed options sentiment in Hims and Hers Health with shares down 9.35%
Press Release: Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
Dow Jones  ·  07-14
Press Release: Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
Hims & Hers Sets Second-quarter Results Release and Investor Call
Reuters  ·  07-14
Hims & Hers Sets Second-quarter Results Release and Investor Call
Hims & Hers's Peptide Opportunity Remains in Focus
Dow Jones  ·  07-10
Hims & Hers's Peptide Opportunity Remains in Focus
Hims & Hers Health is Maintained at Neutral by B of a Securities
Dow Jones  ·  07-09
Hims & Hers Health is Maintained at Neutral by B of a Securities
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Tarsus Pharmaceuticals (TARS)
TIPRANKS  ·  07-09
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS) and Tarsus Pharmaceuticals (TARS)
Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares for $261,540.56
Reuters  ·  07-08
Hims & Hers CFO Oluyemi Okupe Disposes of 7,163 Common Shares for $261,540.56
Trump's FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?
Dow Jones  ·  07-05
Trump's FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?
Hims & Hers Health (HIMS) Secures $400 Million Financing, Is The Upside Already Priced In?
Simply Wall St.  ·  07-02
Hims & Hers Health (HIMS) Secures $400 Million Financing, Is The Upside Already Priced In?
Hims & Hers Health - Receivables Purchase Agreement Has Initial 364-day Term, Extendable by Written Agreement - SEC Filing
THOMSON REUTERS  ·  07-02
Hims & Hers Health - Receivables Purchase Agreement Has Initial 364-day Term, Extendable by Written Agreement - SEC Filing
Hims & Hers Signs USD 400 Million Receivables Purchase Facility with Jpmorgan Chase
Reuters  ·  07-02
Hims & Hers Signs USD 400 Million Receivables Purchase Facility with Jpmorgan Chase
Sector Update: Healthcare
MT Newswires Live  ·  07-02
Sector Update: Healthcare
BofA Securities Adjusts Hims & Hers Health Price Target to $36 From $25, Maintains Neutral Rating
MT Newswires Live  ·  07-01
BofA Securities Adjusts Hims & Hers Health Price Target to $36 From $25, Maintains Neutral Rating
Hims & Hers Health is Maintained at Neutral by B of a Securities
Dow Jones  ·  07-01
Hims & Hers Health is Maintained at Neutral by B of a Securities
HIMS Stock Jumps after Canaccord Raises Price Target to Street-High of $40
TIPRANKS  ·  07-01
HIMS Stock Jumps after Canaccord Raises Price Target to Street-High of $40
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Oruka Therapeutics (ORKA) and Hims & Hers Health (HIMS)
TIPRANKS  ·  07-01
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Oruka Therapeutics (ORKA) and Hims & Hers Health (HIMS)

Introduction

Company Name.
DEFIANCE DAILY TARGET 2X LONG HIMS ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--